Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer

TOP - May 2016, Vol 9, No 2 - Genitourinary Cancers

Results from the large, randomized PIVOT clinical trial that were published in 2012 initially showed that at a median follow-up of 19 years, radical prostatectomy neither improved overall survival nor reduced death related to prostate cancer compared with “watchful waiting” in men with low-risk disease.

However, when these results were published, there was a concern about the generalizability of the results, because of the poorer-than-average overall health of the patients who participated in the PIVOT trial.

Practice Patterns

Stephen A. Mihalcik, MD, PhD, Clinical Fellow, Harvard Radiation Oncology Program, Boston, analyzed the impact of the previously reported PIVOT results by looking at oncology practice patterns before and after the publication of the results from the trial. He reported his new study results at the 2016 Genitourinary Cancers Symposium.

“The study did not directly ask whether doctors are using PIVOT results to guide practice. We looked at practice patterns 15 years before PIVOT and 1 year after PIVOT,” Dr Mihalcik explained.

Dr Mihalcik’s study showed that during the period after the publication of the PIVOT trial results, men with low-risk or favorable intermediate-risk prostate cancer whose health was poorer than the national average were less likely to undergo curative treatment than other men with prostate cancer, whereas men at higher risk for harboring occult high-grade prostate cancer, despite favorable-risk characteristics, were more likely to undergo curative treatment.

“The use of curative therapy was lower among low-risk men who may not benefit from curative treatment, but there is a risk of undertreating men who may be at high risk,” said Dr Mihalcik.

“And there is the possibility that you may overtreat patients who are at risk to die from other causes, such as cardiovascular disease. We want to be sure we are not undertreating high-risk men or overtreating low-risk men. These results are consistent and reassuring, because they are in line with results of PIVOT,” he said.

Patient Characteristics

The new study was based on 6818 men with low-risk (75%) or favorable intermediate-risk (25%) prostate cancer who were treated with curative intent at the Prostate Cancer Foundation of Chicago. The investigators compared the proportion of men with ≥2, 1, or 0 comorbidities, which were restricted to cardiovascular (CV) comorbidities, including myocardial infarction, congestive heart failure, diabetes mellitus, and coronary heart disease.

Of the 6818 men, 5208 had CV comorbidities; 4.3% had ≥2 CV comorbidities, 19.2% had 1 CV comorbidity, and 76.5% had 0 CV comorbidities.

Before the publication of the results of PIVOT, an increasing proportion of men with ≥2 comorbidities received curative treatment over time, whereas 1 month after the study’s results were published, a decline was observed in the proportion of men with the greatest comorbidity (5.4% vs 2.9%; P = .005).

Men who received curative treatment after the publication of PIVOT were significantly more likely to be younger (P = .04), be black or Hispanic (P = .003), and have favorable intermediate-risk prostate cancer than low-risk prostate cancer (P = .007).

Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO 2020
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives published on August 17, 2020 in AACR Highlights
Immune Checkpoint Inhibitor Does Not Improve Outcomes in Metastatic Prostate Cancer
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Prostate Cancer
SBRT plus Immunotherapy in Metastatic Renal-Cell Carcinoma Warrants Further Study
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Immunotherapy
Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Breast Cancer
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
ctDNA May Be a Biomarker for Postsurgery MRD Positivity and Relapse in Patients with NSCLC
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Last modified: April 27, 2020